Larimar (LRMR) Up on Lifting of Partial Clinical Hold on FA Study [Yahoo! Finance]
Larimar Therapeutics, Inc. (LRMR)
Company Research
Source: Yahoo! Finance
Shares of the company were up 8.5% on May 21 following the announcement of the news. Larimar's lead pipeline candidate, nomlabofusp, is being developed for the treatment of patients with Friedreich's ataxia (FA). The candidate is designed to potentially address frataxin deficiency, which is the underlying cause of this rare, progressive and fatal disease of the nervous system. In February 2024, the company completed the four-week, placebo-controlled phase II dose exploration study evaluating nomlabofusp in patients with FA. Treatment with nomlabofusp was generally well-tolerated throughout the four-week treatment period in the study. The abovementioned review by the FDA comprised data from both the 25 mg and 50 mg cohorts in patients who received daily dosing of nomlabofusp for 14 days, followed by dosing on alternate days until day 28. Per the company, at day 14, all the patients (with quantifiable levels at baseline and day 14) who were treated with nomlabofusp (50 mg) achie
Show less
Read more
Impact Snapshot
Event Time:
LRMR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LRMR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LRMR alerts
High impacting Larimar Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
LRMR
News
- Larimar Therapeutics, Inc. (NASDAQ: LRMR) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $25.00 price target on the stock.MarketBeat
- Larimar Therapeutics Selected by FDA to Participate in START Pilot Program for Nomlabofusp in Friedreich's Ataxia [Yahoo! Finance]Yahoo! Finance
- Larimar Therapeutics Selected by FDA to Participate in START Pilot Program for Nomlabofusp in Friedreich’s AtaxiaGlobeNewswire
- Larimar Therapeutics, Inc. (NASDAQ: LRMR) had its price target raised by analysts at Citigroup Inc. from $10.00 to $14.00. They now have a "buy" rating on the stock.MarketBeat
- Larimar Therapeutics, Inc. (NASDAQ: LRMR) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $25.00 price target on the stock.MarketBeat
LRMR
Earnings
- 3/14/24 - Miss
LRMR
Sec Filings
- 6/10/24 - Form 8-K
- 6/3/24 - Form 4
- 5/31/24 - Form 4
- LRMR's page on the SEC website